Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion

计划入组 62 人 · 首次发布于 2014 年 12 月 23 日

Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole

计划入组 220 人 · 首次发布于 2011 年 9 月 7 日

A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion

计划入组 251 人 · 首次发布于 2013 年 6 月 28 日

Ocriplasmin(Jetrea)

focal adhesion kinase

VCAM1-VLA4 inhibitors (Kaken)

Shanghai Haohai Biological Technology Co.,Ltd

China

Acesion Pharma Aps

Sweden

EMA's CHMP Recommends Approval of Novartis' Jetrea for Vitreomacular Traction Treatment

Jingze Bio Files Third HKEX IPO Application, Spotlighting Biosimilar Competition in China's Fertility and Ophthalmology Markets

Polyrizon's Naloxone Hydrogel Shows Superior Nasal Adhesion in Preclinical Study, Potentially Improving Overdose Reversal